Vaccine News and Research

Latest Vaccine News and Research

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011.

13 May 2011

Opinion: Three-pronged approach needed to fight malaria

A closer look provides a valuable reminder that sustained gains against malaria must be built upon a three-legged 'stool'.

13 May 2011

TFAH applauds HHS for new strategic approach to prevent viral hepatitis

The Trust for America's Health applauds the U.S. Department of Health and Human Services for unveiling a new strategic approach to dealing with the silent epidemic of viral hepatitis today.

13 May 2011

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

Cancer studies from Mercer University headline groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC).

13 May 2011

McGill research team finds distinct disease-causing mutations and saves baby girl

About two years ago, Dr. Philippe Gros, a McGill University professor in the Department of Biochemistry and a Principal Investigator in thd McGill Life Sciences Complex, described a mouse mutant that was immunodeficient and hypersensitive to the Bacille Calmette-Gu-rin (BCG) vaccine and to tuberculosis (TB).

12 May 2011

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

12 May 2011

Salmonella enterica bacterium activates virulence genes through Fur protein

Salmonella enterica, one of the main causes of gastrointestinal infections, modulates its virulence gene expression, adapting it to each stage of the infection process, depending on the free iron concentration found in the intestinal epithelium of its host.

12 May 2011

Scientists develop promising vaccine formulations to treat methamphetamine addiction

Scientists are reporting development of three promising formulations that could be used in a vaccine to treat methamphetamine addiction - one of the most serious drug abuse problems in the U.S. The report appears in the Journal of the American Chemical Society.

12 May 2011

VGTI, OHSU's new vaccine candidate may fight against HIV

Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute has developed a vaccine candidate in non-human primates that may eventually lead to a vaccine against Human Immunodeficiency Virus.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

NAA calls for immediate Congressional hearings and scientific investigation into autism-vaccine link

Despite numerous studies cited repeatedly by federal officials as proof that vaccines do not cause autism, a new study released today in the Pace Environmental Law Review revealed that over the last two decades, the National Vaccine Injury Compensation Program has been quietly compensating dozens of vaccine injury cases involving a child with autism.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

While many 16-year-olds are content with PlayStation, Toronto-area student Marshall Zhang used the Canadian SCINET supercomputing network to invent a new drug cocktail which could one day help treat cystic fibrosis.

11 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

First study to look at birth-cohort screening outcomes for hepatitis C virus

New research indicates that screening people born between 1946 and 1970 for hepatitis C virus instead of current risk-based screening practices is cost effective and could lead to 106,000 fewer cases of advanced liver disease and 59,000 fewer HCV-related deaths. An estimated 1.6 million U.S. residents ages 40 to 64 are infected with HCV but do not know it.

10 May 2011

Geron comments on recent European telomerase peptide cancer vaccine patents

Geron Corporation today commented on a ruling from the European Patent Office with regard to its European patent 084139, and the issuance of a second Geron patent covering telomerase peptides, EP1783139.

10 May 2011

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Inhibitex, Inc., announced today that Pfizer Inc. presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine at the 21st European Congress of Clinical Microbiology and Infectious Diseases and 27th International Congress of Chemotherapy in Milan, Italy.

10 May 2011

Mathematical approach can make combination vaccines more affordable for developing countries

Combination vaccines for young children are commonly used in industrialized nations because they provide protection for multiple diseases in one single injection. However, combination vaccines are prohibitively expensive for developing countries and may not available until several years later, or when market prices are more affordable.

10 May 2011